Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape Hawazin Faruki,

Slides:

Advertisements

Similar presentations

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Advertisements

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers Ivana Catacchio, Anna Scattone, Nicola.

Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer–Specific Death in Squamous Cell Carcinoma Shaohua Lu, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification Anna Karlsson, MSc,

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC Stéphane Champiat, MD, Ecaterina Ileana, MD, Giuseppe Giaccone, MD, PhD, Benjamin.

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification Anna Karlsson, MSc,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies Zhong-Yi Dong, PhD, Chao Zhang, MD,

Targets for immunotherapy of liver cancer

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions Kenichi Suda, MD, PhD, Jihye Kim, PhD, Isao Murakami,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,

Detection of Lung Cancer by Automated Sputum Cytometry

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Immunotherapy for Lung Cancer

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Natural History and Factors Associated with Overall Survival in Stage IV ALK- Rearranged Non–Small Cell Lung Cancer Jose M. Pacheco, MD, Dexiang Gao,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Cell-mediated immunity Regulation of the immune response

Carcinoma of the esophagus: Prognostic significance of histologic type

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Vaccines for Lung Cancer

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

Hyun-Sung Lee, MD, PhD, Cynthia Y. Truong, BS, Bryan M. Burt, MD

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune.

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,

Presentation transcript:

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape Hawazin Faruki, DrPH, Gregory M. Mayhew, DrPH, Jonathan S. Serody, MD, D. Neil Hayes, MD, Charles M. Perou, PhD, Myla Lai- Goldman, MD Journal of Thoracic Oncology Volume 12, Issue 6, Pages 943-953 (June 2017) DOI: 10.1016/j.jtho.2017.03.010 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Heatmaps of Bindea et al.6 showing immune cell signature expression, other immune signatures, and individual immune markers in lung adenocarcinoma and squamous cell carcinoma gene expression data sets.1,2 TRU, terminal respiratory unit; PP, proximal proliferative; PI, proximal inflammatory; Tcm, central memory T cell; Tem, effector memory T cell; Th1, type 1 T helper cell; Th2, type 2 T helper cell; TFH, T follicular helper cell; Th17, T-helper 17 cell; Treg, regulatory T cell; Tγδ, γδ T cell; NK, natural killer; DC, dendritic cell; iDC, immature dendritic cell; aDC, activated dendritic cell; pDC, plasmacytoid dendritic cell; IFN, interferon; PD-L1, programmed death ligand 1; PD-L2, programmed death ligand 2; PDCD1, programmed cell death 1; CTLA4, cytotoxic T-lymphocyte associated protein 4; MHC II, major histocompatibility complex class II. Journal of Thoracic Oncology 2017 12, 943-953DOI: (10.1016/j.jtho.2017.03.010) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Association strength (adjusted r2) between CD274 molecule gene (CD274) (programmed death ligand 1 [PD-L1]) expression and immune signature versus strength between subtype and immune signature for 13 adaptive immune cell (AIC) expression signatures in adenocarcinoma (AD) and squamous cell carcinoma (SCC) data sets. Association between subtype and AIC was greater for some AICs in AD and for all AICs tested in SCC. Tcm, central memory T cell; Tem, effector memory T cell; Th1, type 1 T helper cell; Th2, type 2 T helper cell; TFH, T follicular helper cell; Th17, T helper 17 cell; Treg, regulatory T cell; Tγδ, γδ T cell. Journal of Thoracic Oncology 2017 12, 943-953DOI: (10.1016/j.jtho.2017.03.010) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Reproducibility of T-cell signature gene expression subtype patterns across multiple adenocarcinoma data sets2,4,17,18 and squamous cell carcinoma data sets.1,3,16,20 RNA sequencing (RNA-Seq Kit [Illumina, San Diego, CA]) and microarrays from both Affymetrix (Santa Clara, CA) and Agilent (Santa Clara, CA). TCGA, The Cancer Genome Atlas; TRU, terminal respiratory unit; PP, proximal proliferative; PI, proximal inflammatory. Journal of Thoracic Oncology 2017 12, 943-953DOI: (10.1016/j.jtho.2017.03.010) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Adenocarcinoma (AD) and squamous cell carcinoma (SCC) subtype nonsilent mutation burden (A and B), serine/threonine kinase 11 gene (STK11) inactivation (mutation and/or deletion) in AD (C), nuclear factor erythroid 2, like 2 gene (NFE2L2) expression in SCC (D), and major histocompatibility complex class II (MHC II) signature (E and F) with association test p values. Mb, megabase; TRU, terminal respiratory unit; PP, proximal proliferative; PI, proximal inflammatory. Journal of Thoracic Oncology 2017 12, 943-953DOI: (10.1016/j.jtho.2017.03.010) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 5 Subtype-specific immune marker hazard ratios and 95% confidence intervals (CIs) for 5-year overall survival in stage I to III adenocarcinoma (A) and stage I to III squamous cell carcinoma (B). Hazard ratios (HRs) correspond to a unit increase in the normalized immune marker and were adjusted for pathological stage using Cox models. Only markers that were significant (nominal p value <0.05) for at least one subtype are shown. Th1, type 1 T helper cells; Th2, type 2 T helper cells; TFH, T follicular helper cell; Th17, T helper 17 cell; Treg, regulatory T cell; DC, dendritic cell; iDC, immature dendritic cell; PD-L1, programmed death ligand 1; CTLA4, cytotoxic T-lymphocyte associated protein 4; MHC II, major histocompatibility complex class II; TRU, terminal respiratory unit; PP, proximal proliferative; PI, proximal inflammatory. Journal of Thoracic Oncology 2017 12, 943-953DOI: (10.1016/j.jtho.2017.03.010) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions